George Rodgers is a Hematology physician affiliated with University of Utah. OpenAlex indexes 287 publications with 9,652 citations (h-index 45); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1950 Circle Of Hope Dr
Salt Lake City, UT 841125500
Telephone
801-581-2121Provider last certified this registry record 16 Nov 2021.
Clinical trials
- Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia
Sponsor: University of Utah
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Grifols, S.A.Program year20251 payment
- GENZYME CORPORATIONProgram year20254 payments
- Alexion Pharmaceuticals, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
64.6%Factor Xa inhibitor34.8%Eliquis68%Xarelto32%Part D<11 patientsAntifibrinolytic Agent17.1%Tranexamic Acid100%Part D≥18 patients+ 1 more class in this area
Cancer & immunology
28.2%Calcineurin inhibitor13.3%Cyclosporine Modified100%Part D<11 patientsAntimetabolite8.8%Hydroxyurea100%Part D<11 patients+ 1 more class in this area
Sensory organs
7.2%Corticosteroid7.2%Dexamethasone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1995–1995 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Antithrombin Therapy: Current State and Future Outlook
Clinical and Applied Thrombosis/Hemostasis
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Colman, MD
University of Utah
Michael Varner, MD
University of Utah
James Fang
University of Utah
Wallace Akerley, MD
University of Utah
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”